Latest news
Loading news…
Aldagen
ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Durham, North Carolina, United States Founded 2000 11-50 employees For Profit
Aldagen develops regenerative cell therapies for inherited metabolic diseases, leukemia, critical limb ischemia and ischemic heart failure.
Aldagen was acquired by Nuo Therapeutics in 2012.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
1
Patents
2
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 3
- Active products
- 11
- Patents granted
- 2
- Trademarks
- 0
- Top patent class
- a61
- IT spend
- $422.67K
Company Info
- Founded
- 2000
- Employees
- 11-50
- Operating status
- Closed
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 5
- HQ
- Durham, North Carolina, United States
- Region
- Research Triangle, East Coast, Southern US
- Exit date
- Feb 9, 2012
Signals & Scores
- Heat score
- Low
- Trend (7d)
- 0
- Trend (30d)
- -2.3
- Trend (90d)
- -4.3
1
professional contacts at Aldagen
Contact execs at Aldagen →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Aldagen
Loading news…
FAQs about Aldagen
People who checked this page also checked these
Browse the full Acquirezy directory.